Tech Company Financing Transactions
Halia Therapeutics Funding Round
Halia Therapeutics closed a $30 million Series C investment round on 1/31/2024. Investors included private investors.
Transaction Overview
Company Name
Announced On
1/31/2024
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
private investors (Lead Investor) (Todd Pedersen)
Proceeds Purpose
Proceeds from the financing will be used to support the advancement of Halia's lead asset, HT-6184, a selective and orally bioavailable first-in-class inhibitor of NLRP3/NEK7 inflammasome in Phase II clinical trials.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
3900 N. Traverse Mountain Blvd. 100
Lehi, UT 84043
USA
Lehi, UT 84043
USA
Phone
Website
Email Address
Overview
At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Bearss
Chief Financial Officer
Jeff Burton
Chief Medical Officer
Margit Janat-Amsbury
Chief Operating Officer
Jared Bearss
Vice President
Kevin O'Neill
VP - Operations
Paul Flynn
VP - Regulatory Affairs
Lisa Shamon
Browse more venture capital transactions:
Prev: 1/31/2024: Spiden venture capital transaction
Next: 1/31/2024: BlueLayer venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs